GLP—1受体激动剂利西拉肽研究分析(2)
[3]Gaal， L.V.， et al.， Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus[J]. Journal of Clinical & Translational Endocrinology， 2014，1(2)： 31-37.
[4]Yale， J.F.， et al.， Adjunctive lixisenatide Treatment Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus Irrespective of β-cell Function[J].Canadian Journal of Diabetes， 2014，38：S50-S51.
[5]Liu， W.， et al.Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1，2，3，6-tetrahydropyridine mouse model of Parkinson's disease[J].Neuroscience， 2015： 42-50.
[6]Bentley-Lewis， R.， et al.Rationale， design， and baseline characteristics in Evaluation of lixisenatide in Acute Coronary Syndrome， a long-term cardiovascular end point trial of lixisenatide versus placebo[J].American Heart Journal， 2015，169： 631-638.e7.
[7]Werner， H.S.T.H.， 996-P Anti-atherosclerotic Activity of lixisenatide[J].ApoE Knockout Mice，2014.编辑/周芸霏, 百拇医药(唐静 王琴 胡琪)
[4]Yale， J.F.， et al.， Adjunctive lixisenatide Treatment Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus Irrespective of β-cell Function[J].Canadian Journal of Diabetes， 2014，38：S50-S51.
[5]Liu， W.， et al.Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1，2，3，6-tetrahydropyridine mouse model of Parkinson's disease[J].Neuroscience， 2015： 42-50.
[6]Bentley-Lewis， R.， et al.Rationale， design， and baseline characteristics in Evaluation of lixisenatide in Acute Coronary Syndrome， a long-term cardiovascular end point trial of lixisenatide versus placebo[J].American Heart Journal， 2015，169： 631-638.e7.
[7]Werner， H.S.T.H.， 996-P Anti-atherosclerotic Activity of lixisenatide[J].ApoE Knockout Mice，2014.编辑/周芸霏, 百拇医药(唐静 王琴 胡琪)